Breaking News
November 19, 2017 - Dental filling failure linked to smoking, drinking and genetics
November 19, 2017 - Medicaid expansion takes a bite out of medical debt
November 19, 2017 - Study aims to involve parents in early intervention services for children with autism
November 19, 2017 - Don’t Fret Delays in Treating Colon Cancer, Study Suggests
November 19, 2017 - Yeast Infection Test: MedlinePlus Lab Test Information
November 19, 2017 - Video of blood clot contraction reveals how platelets naturally form unobtrusive clots
November 19, 2017 - UNN researchers explore modeling of cognitive dissonance phenomenon
November 19, 2017 - Verseon presents second anticoagulation candidate for clinical trials at AHA 2017
November 19, 2017 - Pregnant Asian women who develop high blood pressure at highest risk for heart failure hospitalization
November 19, 2017 - Medicare seeks comment on ways to cut costs of Part D drugs
November 19, 2017 - Tree cover linked to fewer asthma cases in polluted urban neighborhoods
November 19, 2017 - Make the Diagnosis: Hair Care Conundrum
November 19, 2017 - New techniques give blood biopsies greater promise
November 19, 2017 - Researchers identify possible genetic basis for coronary artery disease
November 19, 2017 - Stress experienced by emergency call handlers has negative impact on psychological health
November 18, 2017 - New cancer cell screening is improving childhood leukaemia treatment
November 18, 2017 - Groundbreaking study identifies protein as potential factor in cancer metastasis
November 18, 2017 - New model to test effectiveness of existing and potential CF therapies
November 18, 2017 - Staying Active May Lower Odds for Glaucoma
November 18, 2017 - Potential new autism drug shows promise in mice
November 18, 2017 - Some states roll back ‘retroactive Medicaid,’ a buffer for the poor — and for hospitals
November 18, 2017 - Selectively deleting stem cell factor promotes recovery after TBI in mice
November 18, 2017 - Breakthrough research brings new procedure closer to helping patients with blood cancer
November 18, 2017 - Dr Peter Simpson Appointed to SLAS Board of Directors
November 18, 2017 - Friendships between young children can protect against ADHD
November 18, 2017 - Old World monkeys could hold key to stop progression of rheumatoid arthritis
November 18, 2017 - Harris Health System RNs named among 20 Outstanding Nurses for 2017
November 18, 2017 - Old World monkeys could be key to a new, powerful rheumatoid arthritis therapy
November 18, 2017 - Mount Sinai researchers identify new therapeutic target for ER+ breast cancer
November 18, 2017 - Age, CRP levels predict success in tapering of biologics in rheumatoid arthritis patients
November 18, 2017 - New dye could be used to observe electrical activity of neurons in the brain
November 18, 2017 - New study further validates use of vaginal progesterone to decrease risk of preterm birth
November 18, 2017 - Russian researcher determined range of reference values for boron in the human body
November 18, 2017 - ‘What the Health?’ Tax bill or health bill?
November 18, 2017 - Could Your Cat Give You ‘Bird Flu?’
November 18, 2017 - Vitamin D Linked to Fertility Outcomes in ART
November 18, 2017 - Neuroscientists identify genetic changes in microglia in a mouse model of neurodegeneration and Alzheimer’s disease
November 18, 2017 - Tax reform proposal could impact care for older Americans
November 18, 2017 - PCSK9 inhibitor offers clinical benefit to patients with peripheral artery disease
November 18, 2017 - Researchers receive £1.3 million to develop sight-saving imaging technology
November 18, 2017 - Novel buckypaper sensor could pave way for high-performance, affordable wearable technology
November 18, 2017 - Despite ACA cost protections, most adolescents skip regular checkups
November 18, 2017 - Stem cell treatment allows paraplegic rats to walk and regain sensory perception
November 18, 2017 - HTC analytical conference comes to the UK
November 18, 2017 - Face It: Drinking, Smoking Takes Toll on Looks: MedlinePlus Health News
November 18, 2017 - New research shows where in the brain the earliest signs of Alzheimer’s occur
November 18, 2017 - Philips announces launch of global movement to raise awareness for COPD
November 18, 2017 - University of Bristol awarded grant to reduce antibacterial drug resistance in Thailand
November 18, 2017 - New oxytocin chemical sensor could be first step towards early diagnosis of autism
November 18, 2017 - Study shows how naïve T-cells may affect tumor immunity and immunotherapy
November 18, 2017 - New studies highlight importance of cardiorespiratory fitness to reduce CVD risk
November 18, 2017 - Study finds medical cannabis is effective at reducing opioid addiction
November 18, 2017 - Specially tailored, ultrafast light pulses can trigger neurons to fire in different patterns
November 18, 2017 - Decrease in sunshine linked to rising incidence of Rickets
November 18, 2017 - Harnessing social media big data to fight against prescription drug crisis
November 18, 2017 - Researchers find way to switch tumor cells between 2D and 3D morphology
November 18, 2017 - Leaf-eating ability of beetle largely due to bacteria inside the insect
November 18, 2017 - FDA Approves Hemlibra (emicizumab-kxwh) for Hemophilia A with Inhibitors
November 18, 2017 - Adolescents underreport amphetamine use, likely unaware that adderall is amphetamine
November 18, 2017 - Study reveals a reduced risk of teenage eczema in breastfed babies
November 18, 2017 - Separating side effects could pave way for safe, effective pain medications
November 18, 2017 - Gut bacteria at young age can contribute to MS disease onset and progression, study suggests
November 18, 2017 - Environmental triggers may play role in development of Lupus
November 18, 2017 - Review looks into conventional versus new treatment modalities in orthodontic pain management
November 17, 2017 - FDA Alert: Diphenoxylate Hydrochloride and Atropine Sulfate Tablets by Greenstone: Recall
November 17, 2017 - For older women, every movement matters
November 17, 2017 - Talking-based therapy could transform aftercare for cancer survivors
November 17, 2017 - Olympus IXplore SpinSR10 imaging system enables researchers to observe fine details in live cells
November 17, 2017 - Study explores reasons for underrepresentation of minorities in genetic cancer research
November 17, 2017 - California firm running physician practices is closing down as scrutiny ramps up
November 17, 2017 - BMI not valid measure of obesity in postmenopausal women, study shows
November 17, 2017 - Vaginal progesterone decreases the risk of premature birth in women with short cervix
November 17, 2017 - Pricey ER Tests for Chest Pain Often Unnecessary
November 17, 2017 - ‘Old’ Lungs May Be Good Transplant Options: MedlinePlus Health News
November 17, 2017 - How not to gain weight over the holidays
November 17, 2017 - Researchers map first-ever proteome of healthy human heart
November 17, 2017 - Drug used to prevent and treat malaria may also be effective for Zika virus
November 17, 2017 - One in 20 children still receiving codeine to treat pain despite warning from federal regulators
November 17, 2017 - Improving clinical trials with machine learning
November 17, 2017 - Experts identify mental exercise program that can reduce risk of dementia
Gene Therapy, New Drug Battle a Rare But Deadly Disease in Kids: MedlinePlus Health News

Gene Therapy, New Drug Battle a Rare But Deadly Disease in Kids: MedlinePlus Health News

image_pdfDownload PDFimage_print

HealthDay news image

WEDNESDAY, Nov. 1, 2017 (HealthDay News) — Babies born with a previously untreatable degenerative nerve disease now have two fresh sources of hope for their future.

Two innovative new therapies for spinal muscular atrophy (SMA) type 1 have proven highly effective in clinical trials, researchers report.

Babies with SMA are born without the gene that promotes production of survival motor neuron (SMN) protein. Without this protein, nerve cells in the spinal cord and brain stem stop working and start to die off.

These babies slowly lose the ability to move their arms and legs. Those with the most severe form, SMA type 1, eventually lose the ability to breathe on their own and rarely survive beyond 2 years of age.

Two research groups say they’ve produced breakthrough therapies for these children.

First, a new genetic treatment employed a DNA-loaded virus to replace the missing SMN1 gene with a fresh, healthy copy of the gene.

Second, an already-approved drug called nusinersen (Spinraza) was used to promote production of the crucial nerve protein by a backup gene called SMN2.

Both approaches increased survival in babies with SMA and preserved or improved their motor function, the researchers said.

“These are the first realistic treatment options for SMA,” said Dr. Ans van der Ploeg. She is chair of the Center for Lysosomal and Metabolic Diseases at Erasmus MC University in Rotterdam, the Netherlands.

Both therapies aim to increase production of SMN protein in the motor neurons and thereby improve the survival and function of motor neurons, she said. This leads to better muscle and respiratory function and survival, added van der Ploeg, who wrote an editorial accompanying the two clinical trial reports.

About one in every 11,000 babies is born with SMA, and six in 10 of them have type 1, said Dr. Richard Finkel. He is chief of neurology at Nemours Children’s Hospital in Orlando, Fla., and lead researcher of the nusinersen clinical trial.

The gene therapy treatment was tested in 15 babies with SMA type 1. All received one intravenous dose of a genetically engineered virus containing the new copy of the SMN gene. The virus is named AVXS-101. This was a phase 1 trial to test safety.

“We are trying to replace SMN1 with enough gene that works in enough nerve cells to change function,” said lead researcher Dr. Jerry Mendell, director of neuromuscular disorders and neurosciences at Nationwide Children’s Hospital in Columbus, Ohio.

All 15 patients treated with AVXS-101 are still alive, Mendell said, and some are thriving. Higher doses produced better responses.

“All the patients in the trial have improved with the exception of one,” Mendell said. “We have patients living out past three years now. And we had patients who actually could walk and run and play.”

Nusinersen was tested in 80 babies at 31 hospitals as part of a phase III trial prior to its 2016 approval.

“The drug is kind of novel,” Finkel said. “It’s not your standard off-the-shelf pharmacy kind of drug. It’s similar to a little piece of DNA.”

The drug targets the SMN2 gene, a backup gene to the SMN1 gene missing in these babies. It is injected into the spinal fluid. Patients undergo four “loading doses” via lumbar punctures within the first two months, and receive maintenance doses every four months, Finkel said.

Nusinersen amps up protein production by the SMN2 gene, potentially halting progression of nerve damage.

In the trial, 41 percent of infants who received the earliest treatment with nusinersen and 51 percent of infants in the final analysis experienced stable or improved motor function, the researchers reported.

Babies treated with nusinersen also were more likely to survive. The risk of death was 63 percent lower in the nusinersen group compared with the control group, the findings showed.

Results were so promising that the clinical trial was halted early so the control group could receive nusinersen, the study authors said.

“This study shows the drug has a clinically meaningful response with a higher likelihood of improved survival and motor function,” Finkel said.

Nusinersen, made by Biogen, is available for treatment now.

AVXS-101 will proceed to broader clinical trials involving more children at multiple hospitals, Mendell said.

Neither treatment had any clinically significant side effects, according to the researchers. The treatments do not constitute a full cure for children who have already developed symptoms of SMA. However, both research teams hope that kids treated before symptoms arise won’t suffer any degenerative nerve loss.

Finkel said, “If we can get these babies before they show these signs of weakness, I think that’s going to give the best chance for the most robust response, possibly even a cure.”

Van der Ploeg added that younger, less severely affected patients had a better chance of a good response in the trials. Also, while the gene therapy pilot trial results are promising, more data are required, she noted.

The nusinersen trial was paid for by Biogen and the drug’s developer, Ionis Pharmaceuticals. The AVXS-101 trial received funding from AveXis, developer of the designer virus.

Results of the studies were published in the Nov. 2 issue of the New England Journal of Medicine.

SOURCES: Ans van der Ploeg, M.D., Ph.D., chair, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, the Netherlands; Richard Finkel, M.D., chief, neurology, Nemours Children’s Hospital, Orlando, Fla.; Jerry Mendell, M.D., director, neuromuscular disorders and neurosciences, Nationwide Children’s Hospital, Columbus, Ohio; Nov. 2, 2017, New England Journal of Medicine

News stories are written and provided by HealthDay and do not reflect federal policy, the views of MedlinePlus, the National Library of Medicine, the National Institutes of Health, or the U.S. Department of Health and Human Services.

Tagged with:

About author

Related Articles